Cardiovascular morbidity and mortality after kidney transplantation

Transplant International

Volumn 28, Issue 1, 2015, Pages 10-21

  Stoumpos, Sokratis ^a   Jardine, Alan G ^a,b   Mark, Patrick B ^a,b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

arrhythmia; atherosclerosis; cardiovascular; hypertension; kidney transplant; lipids; statins

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; REVIEW; SUDDEN CARDIAC DEATH; VASOCONSTRICTION; ADVERSE EFFECTS; BLOOD; COMPLICATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; KIDNEY FAILURE, CHRONIC; LIFESTYLE; MORTALITY; PHYSIOLOGY; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME;

LIPID; STEROID;

CARDIOVASCULAR DISEASES; HUMANS; IMMUNOSUPPRESSION; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIFE STYLE; LIPIDS; QUALITY OF LIFE; RISK FACTORS; STEROIDS; TREATMENT OUTCOME;

EID: 84916205217     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12413     Document Type: Review

References (121)

1. Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K,. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
2. Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams L, Berling DP,. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24: 59.
3. Wolfe RA, Ashby VB, Milford EL, et al,. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
4. Rabbat CG, Thorpe KE, Russell JD, Churchill DN,. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11: 917.
5. Oniscu GC, Brown H, Forsythe JL,. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005; 16: 1859.
6. Glanton CW, Kao TC, Cruess D, Agodoa LY, Abbott KC,. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003; 63: 647.
7. Ojo AO, Hanson JA, Meier-Kriesche H, et al,. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589.
8. Merion RM, Ashby VB, Wolfe RA, et al,. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294: 2726.
9. Snoeijs MG, Schaubel DE, Hené R, et al,. Kidneys from donors after cardiac death provide survival benefit. J Am Soc Nephrol 2010; 21: 1015.
10. Ojo A, Wolfe RA, Agodoa LY, et al,. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66: 1651.
11. Rao PS, Schaubel DE, Wei G, Fenton SS,. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006; 82: 669.
12. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB,. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
13. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
14. Wheeler DC, Steiger J,. Evolution and etiology of cardiovascular diseases in renal transplant recipients. Transplantation 2000; 70: SS41.
15. Levey AS, Beto JA, Coronado BE, et al,. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853.
16. Sarnak MJ, Levey AS, Schoolwerth AC, et al,. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154.
17. Collins AJ, Foley RN, Chavers B, et al,. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis 2014; 63: A7.
18. Pruthi R, Steenkamp R, Feest T,. UK Renal Registry 16th Annual Report: Chapter 8 Survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses. Nephron Clin Pract 2013; 125: 139.
19. Farrugia D, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A,. Death within the first year after kidney transplantation-an observational cohort study. Transpl Int 2014; 27: 262.
20. Zager PG, Nikolic J, Brown RH, et al,. "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54: 561.
21. Liu Y, Coresh J, Eustace JA, et al,. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451.
22. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK,. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560.
23. Lobo ML, Favorito LA, Abidu-Figueiredo M, Sampaio FJ,. Renal pelvic diameters in human fetuses: anatomical reference for diagnosis of fetal hydronephrosis. Urology 2011; 77: 452.
24. Carpenter MA, John A, Weir MR, et al,. BP, cardiovascular disease, and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol 2014; 25: 1554.
25. Jardine AG, Fellström B, Logan JO, et al,. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46: 529.
26. Holdaas H, Fellström B, Jardine AG, et al,. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
27. Shepherd J, Cobbe SM, Ford I, et al,. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301.
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.
29. Kumar N, Baker CS, Chan K, et al,. Cardiac survival after pre-emptive coronary angiography in transplant patients and those awaiting transplantation. Clin J Am Soc Nephrol 2011; 6: 1912.
30. Patel RK, Mark PB, Johnston N, et al,. Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant 2008; 8: 1673.
31. De Lima JJ, Gowdak LH, de Paula FJ, et al,. Treatment of coronary artery disease in hemodialysis patients evaluated for transplant-a registry study. Transplantation 2010; 89: 845.
32. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW,. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation-evidence from the FAVORIT study. Clin Transplant 2012; 26: E438.
33. Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL,. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation 2011; 91: 542.
34. Lentine KL, Brennan DC, Schnitzler MA,. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
35. Collins AJ,. Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003; 325: 163.
36. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B,. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 1662.
37. Wali RK, Wang GS, Gottlieb SS, et al,. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45: 1051.
38. Lentine KL, Schnitzler MA, Abbott KC, et al,. De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis 2005; 46: 720.
39. Stewart GA, Gansevoort RT, Mark PB, et al,. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67: 217.
40. Lenihan CR, Montez-Rath ME, Scandling JD, Turakhia MP, Winkelmayer WC,. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant 2013; 13: 1566.
41. Ojo AO,. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603.
42. Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B,. A cardiovascular risk calculator for renal transplant recipients. Transplantation 2012; 94: 57.
43. Kasiske BL, Anjum S, Shah R, et al,. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
44. Premasathian NC, Muehrer R, Brazy PC, Pirsch JD, Becker BN,. Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens 2004; 18: 871.
45. Mangray M, Vella JP,. Hypertension after kidney transplant. Am J Kidney Dis 2011; 57: 331.
46. Ducloux D, Kazory A, Chalopin JM,. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66: 441.
47. Opelz G, Wujciak T, Ritz E,. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217.
48. Mange KC, Cizman B, Joffe M, Feldman HI,. Arterial hypertension and renal allograft survival. JAMA 2000; 283: 633.
49. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337.
50. Opelz G, Döhler B, Study CT,. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
51. Midtvedt K, Hartmann A, Foss A, et al,. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72: 1787.
52. van Riemsdijk IC, Mulder PG, de Fijter JW, et al,. Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-controlled, multi-center study. Transplantation 2000; 70: 122.
53. Kuypers DR, Neumayer HH, Fritsche L, et al,. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204.
54. Rahn KH, Barenbrock M, Fritschka E, et al,. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354: 1415.
55. McCulloch TA, Harper SJ, Donnelly PK, et al,. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 1994; 47: 839.
56. Ladefoged SD, Andersen CB,. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8: 128.
57. Mourad G, Ribstein J, Mimran A,. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43: 419.
58. Cross NB, Webster AC, Masson P, O'connell PJ, Craig JC,. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88: 7.
59. Paoletti E, Bellino D, Marsano L, Cassottana P, Rolla D, Ratto E,. Effects of ACE inhibitors on long-term outcome of renal transplant recipients: a randomized controlled trial. Transplantation 2013; 95: 889.
60. Philipp T, Martinez F, Geiger H, et al,. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25: 967.
61. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA,. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350.
62. Opelz G, Döhler B,. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation 2013; [Epub ahead of print].
63. Gaston RS, Kasiske BL, Fieberg AM, et al,. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
64. Schena FP, Pascoe MD, Alberu J, et al,. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
65. Artz MA, Boots JM, Ligtenberg G, et al,. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880.
66. Holdaas H, Fellström B, Cole E, et al,. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929.
67. Holdaas H, Fellström B, Jardine AG, et al,. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 2005; 20: 974.
68. Jardine AG, Holdaas H, Fellström B, et al,. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988.
69. Ballantyne CM, Corsini A, Davidson MH, et al,. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553.
70. Palmer SC, Navaneethan SD, Craig JC, et al,. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2014; 1: CD005019.
71. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259.
72. Woodward RS, Schnitzler MA, Baty J, et al,. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590.
73. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM,. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732.
74. Valderhaug TG, Jenssen T, Hartmann A, et al,. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429.
75. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ,. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178.
76. Sharif A, Baboolal K,. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012; 8: 34.
77. Gaston RS, Basadonna G, Cosio FG, et al,. Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis 2004; 44: 529.
78. Ducloux D, Kazory A, Chalopin JM,. Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: a prospective study. Transplantation 2005; 79: 438.
79. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S,. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56: 1127.
80. Fellström B, Jardine AG, Soveri I, et al,. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986.
81. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY,. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2358.
82. Weiner DE, Carpenter MA, Levey AS, et al,. Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 2012; 12: 2437.
83. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P,. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462.
84. Parfrey PS, Harnett JD, Foley RN, et al,. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60: 908.
85. Dudziak M, Debska-Slizień A, Rutkowski B,. Cardiovascular effects of successful renal transplantation: a 30-month study on left ventricular morphology, systolic and diastolic functions. Transplant Proc 2005; 37: 1039.
86. Patel RK, Mark PB, Johnston N, McGregor E, Dargie HJ, Jardine AG,. Renal transplantation is not associated with regression of left ventricular hypertrophy: a magnetic resonance study. Clin J Am Soc Nephrol 2008; 3: 1807.
87. Rigatto C, Parfrey P,. Therapy insight: management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2006; 2: 514.
88. Ventura JE, Tavella N, Romero C, Petraglia A, Báez A, Muñoz L,. Aortic valve calcification is an independent factor of left ventricular hypertrophy in patients on maintenance haemodialysis. Nephrol Dial Transplant 2002; 17: 1795.
89. Ibernon M, Moreso F, Ruiz-Majoral A, et al,. Contribution of anemia and hypertension to left ventricular hypertrophy during the initial 2 years after renal transplantation. Transplant Proc 2011; 43: 2199.
90. Hernández D, Lacalzada J, Salido E, et al,. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney Int 2000; 58: 889.
91. Paoletti E, Cassottana P, Amidone M, Gherzi M, Rolla D, Cannella G,. ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial. Am J Kidney Dis 2007; 50: 133.
92. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G,. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52: 324.
93. Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G,. Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 2012; 93: 503.
94. Kurtz A, Della Bruna R, Kühn K,. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int 1988; 33: 947.
95. Mason J, Müller-Schweinitzer E, Dupont M, et al,. Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991; 32: S28.
96. Mourer JS, de Koning EJ, van Zwet EW, Mallat MJ, Rabelink TJ, de Fijter JW,. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. Transplantation 2013; 96: 49.
97. Mulay AV, Hussain N, Fergusson D, Knoll GA,. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748.
98. Ekberg H, Bernasconi C, Tedesco-Silva H, et al,. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
99. Egbuna OI, Davis RB, Chudinski R, et al,. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Transplantation 2009; 88: 684.
100. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
101. Cosio FG, Falkenhain ME, Pesavento TE, et al,. Patient survival after renal transplantation: II. The impact of smoking. Clin Transplant 1999; 13: 336.
102. Kasiske BL, Klinger D,. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol 2000; 11: 753.
103. Group KDIGOKTW. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 3): S1.
104. Baker R, Jardine A, Andrews P,. Renal Association Clinical Practice Guideline on post-operative care of the kidney transplant recipient. Nephron Clin Pract 2011; 118 (Suppl. 1): c311.
105. de Vries AP, Bakker SJ, van Son WJ, et al,. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
106. Meier-Kriesche HU, Arndorfer JA, Kaplan B,. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002; 73: 70.
107. Abbott KC, Reynolds JC, Taylor AJ, Agodoa LY,. Hospitalized atrial fibrillation after renal transplantation in the United States. Am J Transplant 2003; 3: 471.
108. Zelle DM, Corpeleijn E, Stolk RP, et al,. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6: 898.
109. Didsbury M, McGee RG, Tong A, et al,. Exercise training in solid organ transplant recipients: a systematic review and meta-analysis. Transplantation 2013; 95: 679.
110. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM,. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 2000; 11: 134.
111. Bostom AG, Carpenter MA, Kusek JW, et al,. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011; 123: 1763.
112. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J,. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084.
113. Abedini S, Holme I, März W, et al,. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246.
114. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
115. Haidinger M, Werzowa J, Hecking M, et al,. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014; 14: 115.
116. Hecking M, Haidinger M, Döller D, et al,. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739.
117. Woodle ES, First MR, Pirsch J, et al,. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
118. Vincenti F, Schena FP, Paraskevas S, et al,. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
119. Rizzari MD, Suszynski TM, Gillingham KJ, et al,. Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol 2012; 7: 494.
120. Vanrenterghem Y, Lebranchu Y, Hené R, Oppenheimer F, Ekberg H,. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352.
121. Ahsan N, Hricik D, Matas A, et al,. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865.